RE-BVS – Piemonte Repository

Sfoglia per AUTORE
MAZIERES J
Collezione AOU San Luigi di Orbassano

Items : 11

Sotorasib versus docetaxel for previously treated KRAS G12C-mutated non-small-cell lung cancer: a plain language summary. in Future oncology (London, England) / Future Oncol. 2025 Mar 24:1-12. doi: 10.1080/14796694.2025.2474789.

2025
AOU San Luigi di Orbassano

de Langen AJ; Johnson ML; Mazieres J; Dingemans AC; Mountzios G; Pless M; Wolf J; Schuler M; Lena H; Skoulidis F; Yoneshima Y; Kim SW; Linardou H; Novello S; van der Wekken AJ; Chen Y; Peters S; Felip E; Solomon BJ; Ramalingam SS; Dooms C; Lindsay CR; Ferreira CG; Blais N; Obiozor CC; Wang Y; Mehta B; Varrieur T; Ngarmchamnanrith G; et alii...

Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRAS(G12C) mutation: a randomised, open-label, phase 3 trial. in Lancet (London, England) / Lancet. 2023 Mar 4;401(10378):733-746. doi: 10.1016/S0140-6736(23)00221-0. Epub 2023 Feb 7.

2023
AOU San Luigi di Orbassano

Results of screening in early and advanced thoracic malignancies in the EORTC pan-European SPECTAlung platform. in Scientific reports / Sci Rep. 2022 May 18;12(1):8342. doi: 10.1038/s41598-022-12056-0.

2022
AOU San Luigi di Orbassano

Morfouace M; Novello S; Stevovic A; Dooms C; Janži? U; Berghmans T; Dziadziuszko R; Gorlia T; Felip E; Paz-Ares L; Mazieres J; O'Brien M; Bironzo P; Vansteenkiste J; Lacroix L; Dingemans AC; Golfinopoulos V; Besse B;

How far we have come targeting BRAF-mutant non-small cell lung cancer (NSCLC). in Cancer treatment reviews / Cancer Treat Rev. 2022 Feb;103:102335. doi: 10.1016/j.ctrv.2021.102335. Epub 2021 Dec 31.

2022
AOU San Luigi di Orbassano

Tabbò F; Pisano C; Mazieres J; Mezquita L; Nadal E; Planchard D; Pradines A; Santamaria D; Swalduz A; Ambrogio C; Novello S; Ortiz-Cuaran S; Tabbò F; Pisano C; Mazieres J; Mezquita L; Nadal E; Planchard D; Pradines A; Santamaria D; Swalduz A; Ambrogio C; Novello S; Ortiz-Cuaran S;

Efficacy of Brigatinib in Patients With Advanced ALK-Positive NSCLC Who Progressed on Alectinib or Ceritinib: ALK in Lung Cancer Trial of brigAtinib-2 (ALTA-2). in Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer / J Thorac Oncol. 2022 Dec;17(12):1404-1414. doi: 10.1016/j.jtho.2022.08.018. Epub 2022 Sep 10.

2022
AOU San Luigi di Orbassano

Ou SI; Nishio M; Ahn MJ; Mok T; Barlesi F; Zhou C; Felip E; de Marinis F; Kim SW; Pérol M; Liu G; Migliorino MR; Kim DW; Novello S; Bearz A; Garrido P; Mazieres J; Morabito A; Lin HM; Yang H; Niu H; Zhang P; Kim ES;

Veliparib in Combination With Platinum-Based Chemotherapy for First-Line Treatment of Advanced Squamous Cell Lung Cancer: A Randomized, Multicenter Phase III Study. in Journal of clinical oncology : official journal of the American Society of Clinical Oncology / J Clin Oncol. 2021 Nov 10;39(32):3633-3644. doi: 10.1200/JCO.20.03318. Epub 2021 Aug 26.

2021
AOU San Luigi di Orbassano

Ramalingam SS; Novello S; Guclu SZ; Bentsion D; Zvirbule Z; Szilasi M; Bernabe R; Syrigos K; Byers LA; Clingan P; Bar J; Vokes EE; Govindan R; Dunbar M; Ansell P; He L; Huang X; Sehgal V; Glasgow J; Bach BA; Mazieres J;

Health-Related Quality of Life With Carboplatin-Paclitaxel or nab-Paclitaxel With or Without Pembrolizumab in Patients With Metastatic Squamous Non-Small-Cell Lung Cancer. in Journal of clinical oncology : official journal of the American Society of Clinical Oncology / J Clin Oncol. 2020 Jan 20;38(3):271-280. doi: 10.1200/JCO.19.01348. Epub 2019 Nov 21.

2020
AOU San Luigi di Orbassano

Mazieres J; Kowalski D; Luft A; Vicente D; Tafreshi A; Gümü? M; Laktionov K; Hermes B; Cicin I; Rodríguez-Cid J; Wilson J; Kato T; Ramlau R; Novello S; Reddy S; Kopp HG; Piperdi B; Li X; Burke T; Paz-Ares L; Mazieres J; Kowalski D; Luft A; Vicente D; Tafreshi A; Gümü? M; Laktionov K; Hermes B; Cicin I; et alii...

A Brief Report of Transformation From NSCLC to SCLC: Molecular and Therapeutic Characteristics. in Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer / J Thorac Oncol. 2019 Jan;14(1):130-134. doi: 10.1016/j.jtho.2018.08.2028. Epub 2018 Sep 11.

2019
AOU San Luigi di Orbassano

Ferrer L; Giaj Levra M; Brevet M; Antoine M; Mazieres J; Rossi G; Chiari R; Westeel V; Poudenx M; Letreut J; Gervais R; Osman G; Girard N; Toffart AC; Novello S; Moro-Sibilot D;

Efficacy and safety of long-acting pasireotide or everolimus alone or in combination in patients with advanced carcinoids of the lung and thymus (LUNA): an open-label, multicentre, randomised, phase 2 trial. in The Lancet. Oncology / Lancet Oncol. 2017 Dec;18(12):1652-1664. doi: 10.1016/S1470-2045(17)30681-2. Epub 2017 Oct 23.

2017
AOU San Luigi di Orbassano

Ferolla P; Brizzi MP; Meyer T; Mansoor W; Mazieres J; Do Cao C; Léna H; Berruti A; Damiano V; Buikhuisen W; Grønbæk H; Lombard-Bohas C; Grohé C; Minotti V; Tiseo M; De Castro J; Reed N; Gislimberti G; Singh N; Stankovic M; Öberg K; Baudin E;

Scientific Advances in Lung Cancer 2015. in Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer / J Thorac Oncol. 2016 May;11(5):613-638. doi: 10.1016/j.jtho.2016.03.012. Epub 2016 Mar 22.

2016
AOU San Luigi di Orbassano

Tsao AS; Scagliotti GV; Bunn PA Jr; Carbone DP; Warren GW; Bai C; de Koning HJ; Yousaf-Khan AU; McWilliams A; Tsao MS; Adusumilli PS; Rami-Porta R; Asamura H; Van Schil PE; Darling GE; Ramalingam SS; Gomez DR; Rosenzweig KE; Zimmermann S; Peters S; Ignatius Ou SH; Reungwetwattana T; Jänne PA; Mok TS; Wakelee HA; Pirker R; Mazières J; Brahmer JR; Zhou Y; et alii...

A phase II randomized study evaluating the addition of iniparib to gemcitabine plus cisplatin as first-line therapy for metastatic non-small-cell lung cancer. in Annals of oncology : official journal of the European Society for Medical Oncology / Ann Oncol. 2014 Nov;25(11):2156-2162. doi: 10.1093/annonc/mdu384. Epub 2014 Aug 19.

2014
AOU San Luigi di Orbassano

Novello S; Besse B; Felip E; Barlesi F; Mazieres J; Zalcman G; von Pawel J; Reck M; Cappuzzo F; Ferry D; Carcereny E; Santoro A; Garcia-Ribas I; Scagliotti G; Soria JC;